American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
AUTOR(ES)
Marques, Sílvio Alencar
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
29/07/2019
RESUMO
Abstract: Pentavalent antimonials are the first-line drug treatment for American tegumentary leishmaniasis. We report on a patient with chronic renal failure on hemodialysis who presented with cutaneous lesions of leishmaniasis for four months. The patient was treated with intravenous meglumine under strict nephrological surveillance, but cardiotoxicity, acute pancreatitis, pancytopenia, and cardiogenic shock developed rapidly. Deficient renal clearance of meglumine antimoniate can result in severe toxicity, as observed in this case. These side effects are related to cumulative plasma levels of the drug. Therefore, second-line drugs like amphotericin B are a better choice for patients on dialysis.
Documentos Relacionados
- American tegumentary leishmaniasis: diagnostic and treatment challenges in a clinical case
- American tegumentary leishmaniasis: correlations among immunological, histopathological and clinical parameters
- Periungual tegumentary leishmaniasis: a diagnostic challenge
- Diagnostic accuracy of Enzyme-Linked Immunosorbent Assays to detect anti-Leishmania antibodies in patients with American Tegumentary Leishmaniasis: a systematic review
- Disseminated cutaneous leishmaniasis: a patient with 749 lesions